Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report

Diabetology International - 2016
Atsushi Goto1, Hiroshi Noto2, Minoru Noda3, Kohjiro Ueki4, Masato Kasuga5, Naoko Tajima6, Ken Ohashi7, Ryuichi Sakai8, Shoichiro Tsugane9, Nobuyuki Hamajima10, Kazuo Tajima11, Kohzoh Imai12, Hitoshi Nakagama13
1Tokyo Women's Medical University, Tokyo, Japan
2St Luke's International Hospital, Tokyo, Japan
3Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan
4Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
5National Center for Global Health and Medicine, Tokyo, Japan
6Jikei University School of Medicine, Tokyo, Japan
7Department of General Internal Medicine, Dentistry, and Oncologic Emergencies, National Cancer Center Hospital, Tokyo, Japan
8Department of Biochemistry, Kitasato University School of Medicine, Sagamihara, Japan
9National Cancer Center Research Center for Cancer Prevention and Screening, Tokyo, Japan
10Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan
11Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, Tsu, Japan
12Center for Antibody and Vaccine Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
13National Cancer Center Research Institute, Tokyo, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Goto A, Noto H, Noda M, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer, Second Report. J Japan Diabetes Soc. 2016;59(3):174–77. doi: 10.11213/tonyobyo.59.174 (In Japanese)

Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int. 2013;4(2):81–96.

Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17(4):616–28.

Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.

Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.

Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54(7):1608–14.

Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54(1):25–31.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–53.

UK Prospective Diabetes Study. UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet. 1998;352(9131):854–65.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterrans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.

Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–60.

Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjornsdottir S. HbA1C and cancer risk in patients with type 2 diabetes–a nationwide population-based prospective cohort study in Sweden. PLoS One. 2012;7(6):e38784.

Onitilo AA, Stankowski RV, Berg RL, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23(2):134–40.

Thông tin
Thông tin xuất bản

Diabetology International

Thông tin tác giả